-
Christmas 2020 roundup from the TherapeutAix team
As 2020 draws to a close, the team at TheraeutAix has been looking back and reflecting on the last 12…
3 -
Drug Development in IPF
Drug development in Idiopathic Pulmonary Fibrosis (IPF) remains challenging. The pharmacological properties of the two approved drugs, pirfenidone and nintedanib,…
-
Alderley Analytical and Peak Proteins join the TherapeutAix Network
Following a recent collaboration, TherapeutAix is delighted to announce the addition of Alderley Analytical and Peak Proteins as network partners.…
-
TherapeutAix turns two!
This September, TherapeutAix is two years old. Here, we look back on the past 12 months, and take a sneak…
-
COVID-19 and Learning about Lung Fibrosis
Emerging understanding of the clinical course of COVID-19 may enable a better understanding of fibrosis in the lung. Future learnings…
-
Common denominators in fibrotic lung disease
With fibrotic disease being one of our areas of interest, it has been highly interesting to follow the news in…
-
TherapeutAix to attend Fraunhofer ‘Models of Lung Disease’ seminar
Two directors of TherapeutAix, Simon Cruwys and Darcey Black, will be attending the 19th Fraunhofer Seminar titled ‘Models of Lung…
-
2019 Round Up – A Full Year!
With 2019 coming to a close, we’re reflecting on a year filled with activities including: advising clients on their projects,…
-
Drug Development in IPF – An Open Innovation Workshop
From the inception of TherapeutAix, a key aim has been to bring decision-making information within reach of smaller organisations. Frequently…
-
TherapeutAix to present at the Anti-Fibrotic Drug Development Summit in Boston
We are proud partners for the 3rd Annual Anti-Fibrotic Drug Development Summit (AFDD) which will take place on November 18-20th…
